Johnson & Johnson vs Merck & stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Johnson & Johnson is more profitable and has less debt. Merck & grows faster and is cheaper for its profits.
Side by side
| Johnson & Johnson | Merck & | |
|---|---|---|
| $651 billion | $330 billion | |
| 28.5% | 28.1% | |
| +2.7% | +9.4% | |
| 24.3× | 18.1× | |
| 0.7 years | 1.2 years | |
| 21.0% | 17.8% | |
| 2.3% | 2.8% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Johnson & Johnson vs Merck KGaA · Johnson & Johnson vs Moderna · Johnson & Johnson vs Novo Nordisk · Johnson & Johnson vs Novartis · Merck & vs Eli Lilly · Merck & vs McKesson · Merck & vs Merck KGaA · Merck & vs Moderna

